Supporting Information

Reeves et al. 10.1073/pnas.1114966108



Fig. S1. HCMV up-regulates MCL-1 mRNA expression in myeloid cells. (*A* and *B*) RT-PCR analysis for MCL-1, IE72, and actin expression was performed on RNA isolated from mock (bar 1), PMA-treated (bar 2), or HCMV-infected (bars 3 and 4) THP1 cells (*A*) and primary $CD14^{+}/CD34^{+}$ cells (*B*).



Fig. S2. HCMV-mediated protection of THP1 cells from cisplatin A-induced cell death is gB-dependent. (*A*) HCMV preincubated with anti-gB (bars 11–14) or anti-gH (bars 5–8) antibody was used to infect THP1 cells which, 2 h post infection (hpi), were incubated with 0.1% DMSO (bars 5, 7, 11, and 13) or cisplatin A (bars 6, 8, 12, and 14) for 3 h, then rescued in fresh media. As controls, the anti-gB (bars 15 and 16) and anti-gH (bars 9 and 10) were incubated directly with cells in the absence of HCMV infection. Cell viability was then measured by trypan blue staining at 24 hpi. (*B*) HCMV preincubated with no antibody, anti-gB (1 μg/mL) or anti-gH (10 μg/mL) blocking antibodies for 1 h was used to infect fibroblasts. At 24 hpi, cells were stained for viral IE gene expression and counterstained with DAPI to evaluate infectivity.



Fig. S3. HCMV-induced activation of the MCL-1 promoter in THP1 cells is ERK–MAPK-dependent. (*A*) A pGL3 plasmid encoding luciferase under the control of the MCL-1 promoter (pGL3-MCL1) was transfected into THP1 cells (bars 2–8) and, 24 h after transfection, incubated with 0.1% DMSO (bar 3), 10 μM PD98059 (bar 4), 25 μM SB203580 (bar 5), 25 μM SB202474 (bar 6), 10 μM SPB600125 (bar 7), or JNK negative control (bar 8), and assayed for luciferase expression 8 h later. (*B*) THP1 cells transfected with pGL3-MCL-1 were pretreated with DMSO, ERK inhibitor, or inactive analogue and then infected with UV-inactivated HCMV, and luciferase measured 16 h later. (*C*) RT-PCR for MCL-1 and actin gene expression was performed on DNase-treated total RNA isolated 1 hpi from mock- (bars 1–3) or HCMV (bars 4–6)-infected cells pretreated with 0.1% DMSO (bars 1 and 4), ERK inhibitor PD98059 (bars 2 and 5), or p38 inhibitor SB203580 (bars 3 and 6) for 1 h.